Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 465

1.

Author Correction: Phosphorylated HBO1 at UV irradiated sites is essential for nucleotide excision repair.

Niida H, Matsunuma R, Horiguchi R, Uchida C, Nakazawa Y, Motegi A, Nishimoto K, Sakai S, Ohhata T, Kitagawa K, Moriwaki S, Nishitani H, Ui A, Ogi T, Kitagawa M.

Nat Commun. 2018 Apr 20;9:16214. doi: 10.1038/ncomms16214.

PMID:
29676391
2.

Architecture of the complete oxygen-sensing FixL-FixJ two-component signal transduction system.

Wright GSA, Saeki A, Hikima T, Nishizono Y, Hisano T, Kamaya M, Nukina K, Nishitani H, Nakamura H, Yamamoto M, Antonyuk SV, Hasnain SS, Shiro Y, Sawai H.

Sci Signal. 2018 Apr 10;11(525). pii: eaaq0825. doi: 10.1126/scisignal.aaq0825.

PMID:
29636388
3.

Mutations at multiple CDK phosphorylation consensus sites on Cdt2 increase the affinity of CRL4Cdt2 for PCNA and its ubiquitination activity in S phase.

Nukina K, Hayashi A, Shiomi Y, Sugasawa K, Ohtsubo M, Nishitani H.

Genes Cells. 2018 Mar;23(3):200-213. doi: 10.1111/gtc.12563. Epub 2018 Feb 9.

PMID:
29424068
4.

Phosphorylated HBO1 at UV irradiated sites is essential for nucleotide excision repair.

Niida H, Matsunuma R, Horiguchi R, Uchida C, Nakazawa Y, Motegi A, Nishimoto K, Sakai S, Ohhata T, Kitagawa K, Moriwaki S, Nishitani H, Ui A, Ogi T, Kitagawa M.

Nat Commun. 2017 Jul 18;8:16102. doi: 10.1038/ncomms16102. Erratum in: Nat Commun. 2018 Apr 20;9:16214.

5.

Thymine DNA glycosylase modulates DNA damage response and gene expression by base excision repair-dependent and independent mechanisms.

Nakamura T, Murakami K, Tada H, Uehara Y, Nogami J, Maehara K, Ohkawa Y, Saitoh H, Nishitani H, Ono T, Nishi R, Yokoi M, Sakai W, Sugasawa K.

Genes Cells. 2017 Apr;22(4):392-405. doi: 10.1111/gtc.12481. Epub 2017 Mar 20.

6.

Mismatch repair proteins recruited to ultraviolet light-damaged sites lead to degradation of licensing factor Cdt1 in the G1 phase.

Tanaka M, Takahara M, Nukina K, Hayashi A, Sakai W, Sugasawa K, Shiomi Y, Nishitani H.

Cell Cycle. 2017 Apr 3;16(7):673-684. doi: 10.1080/15384101.2017.1295179. Epub 2017 Feb 22.

7.

Control of Genome Integrity by RFC Complexes; Conductors of PCNA Loading onto and Unloading from Chromatin during DNA Replication.

Shiomi Y, Nishitani H.

Genes (Basel). 2017 Jan 26;8(2). pii: E52. doi: 10.3390/genes8020052. Review.

8.

Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.

Terazawa T, Goto M, Miyamoto T, Asaishi K, Shimamoto F, Kuwakado S, Nishitani H, Kii T, Higuchi K.

Intern Med. 2015;54(23):2969-73. doi: 10.2169/internalmedicine.54.5325. Epub 2015 Dec 1.

9.

[A Case of Esophageal Neuroendocrine Carcinoma for Which Irinotecan and Cisplatin Combination Therapy Was Effective].

Shimamoto F, Kii T, Goto M, Kuwakado S, Nishitani H, Terazawa T, Asaishi K, Miyamoto T, Kurisu Y, Higuchi K.

Gan To Kagaku Ryoho. 2015 Aug;42(8):993-6. Japanese.

PMID:
26321716
10.

Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients.

Terazawa T, Nishitani H, Kato K, Hashimoto H, Akiyoshi K, Ito Y, Nakamoto A, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Shimada Y.

Asia Pac J Clin Oncol. 2017 Apr;13(2):e132-e137. doi: 10.1111/ajco.12405. Epub 2015 Aug 6.

PMID:
26245851
11.

Mitotic UV irradiation induces a DNA replication-licensing defect that potentiates G1 arrest response.

Morino M, Nukina K, Sakaguchi H, Maeda T, Takahara M, Shiomi Y, Nishitani H.

PLoS One. 2015 Mar 23;10(3):e0120553. doi: 10.1371/journal.pone.0120553. eCollection 2015.

12.

RanBP9 modulates AICD localization and transcriptional activity via direct interaction with Tip60.

Domingues SC, Konietzko U, Henriques AG, Rebelo S, Fardilha M, Nishitani H, Nitsch RM, da Cruz E Silva EF, da Cruz E Silva OA.

J Alzheimers Dis. 2014;42(4):1415-33. doi: 10.3233/JAD-132495.

PMID:
25024339
13.

Imaging analysis to determine chromatin binding of the licensing factor MCM2-7 in mammalian cells.

Morino M, Tanaka M, Shiomi Y, Nishitani H.

Methods Mol Biol. 2014;1170:529-37. doi: 10.1007/978-1-4939-0888-2_29.

PMID:
24906334
14.

Chromatin fractionation analysis of licensing factors in mammalian cells.

Nishitani H, Morino M, Murakami Y, Maeda T, Shiomi Y.

Methods Mol Biol. 2014;1170:517-27. doi: 10.1007/978-1-4939-0888-2_28.

PMID:
24906333
15.

PCNA-dependent ubiquitination of Cdt1 and p21 in mammalian cells.

Hayashi A, Suenaga N, Shiomi Y, Nishitani H.

Methods Mol Biol. 2014;1170:367-82. doi: 10.1007/978-1-4939-0888-2_19.

PMID:
24906324
16.

Imaging analysis of cell cycle-dependent degradation of Cdt1 in mammalian cells.

Shiomi Y, Suenaga N, Tanaka M, Hayashi A, Nishitani H.

Methods Mol Biol. 2014;1170:357-65. doi: 10.1007/978-1-4939-0888-2_18.

PMID:
24906323
17.

The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.

Terazawa T, Nishitani H, Kato K, Hashimoto H, Akiyoshi K, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Shimada Y.

Anticancer Res. 2014 Feb;34(2):1053-6.

PMID:
24511054
18.

Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer.

Terazawa T, Iwasa S, Takashima A, Nishitani H, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y.

J Cancer Res Clin Oncol. 2013 Dec;139(12):2111-6. doi: 10.1007/s00432-013-1537-7. Epub 2013 Oct 16.

PMID:
24129809
19.

Alternative replication factor C protein, Elg1, maintains chromosome stability by regulating PCNA levels on chromatin.

Shiomi Y, Nishitani H.

Genes Cells. 2013 Nov;18(11):946-59. doi: 10.1111/gtc.12087. Epub 2013 Aug 13.

20.

Cell cycle-dependent subcellular translocation of the human DNA licensing inhibitor geminin.

Dimaki M, Xouri G, Symeonidou IE, Sirinian C, Nishitani H, Taraviras S, Lygerou Z.

J Biol Chem. 2013 Aug 16;288(33):23953-63. doi: 10.1074/jbc.M113.453092. Epub 2013 Jun 29.

21.

Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.

Yoshida M, Goto M, Kii T, Nishitani H, Kawabe S, Kuwakado S, Asaishi K, Miyamoto T, Higuchi K.

Digestion. 2013;87(1):59-64. doi: 10.1159/000343943. Epub 2013 Jan 21.

22.

[Comparison of chemotherapy side effects between elderly and young subjects].

Goto E, Hosomi M, Nishihara M, Goto M, Yoshida M, Kii T, Kuwakado S, Nishitani H, Kawaharada T, Takiuchi H.

Gan To Kagaku Ryoho. 2012 Dec;39(13):2527-31. Japanese.

PMID:
23235173
23.

Inhibition of DNA damage-induced apoptosis through Cdc7-mediated stabilization of Tob.

Suzuki T, Tsuzuku J, Hayashi A, Shiomi Y, Iwanari H, Mochizuki Y, Hamakubo T, Kodama T, Nishitani H, Masai H, Yamamoto T.

J Biol Chem. 2012 Nov 23;287(48):40256-65. doi: 10.1074/jbc.M112.353805. Epub 2012 Oct 12.

24.

Checkpoint kinase ATR phosphorylates Cdt2, a substrate receptor of CRL4 ubiquitin ligase, and promotes the degradation of Cdt1 following UV irradiation.

Sakaguchi H, Takami T, Yasutani Y, Maeda T, Morino M, Ishii T, Shiomi Y, Nishitani H.

PLoS One. 2012;7(9):e46480. doi: 10.1371/journal.pone.0046480. Epub 2012 Sep 28.

25.

A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.

Ogawa K, Ueno T, Kato K, Nishitani H, Akiyoshi K, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Hosokawa A, Sugiyama T, Shimada Y.

Int J Clin Oncol. 2013 Dec;18(6):1020-4. doi: 10.1007/s10147-012-0478-5. Epub 2012 Sep 27.

PMID:
23011103
26.

IAA8 involved in lateral root formation interacts with the TIR1 auxin receptor and ARF transcription factors in Arabidopsis.

Arase F, Nishitani H, Egusa M, Nishimoto N, Sakurai S, Sakamoto N, Kaminaka H.

PLoS One. 2012;7(8):e43414. doi: 10.1371/journal.pone.0043414. Epub 2012 Aug 17.

27.

Retroperitoneal fibrosis in a patient with gastric cancer manifested by lower extremity edema and hydrocele.

Yokoyama R, Tazaki R, Morita H, Nishitani H, Ariumi S, Osuga S, Sohmiya K, Kono T, Narumi Y, Tsuji M, Ishizaka N.

Intern Med. 2012;51(16):2157-60. Epub 2012 Aug 15.

28.

Two different replication factor C proteins, Ctf18 and RFC1, separately control PCNA-CRL4Cdt2-mediated Cdt1 proteolysis during S phase and following UV irradiation.

Shiomi Y, Hayashi A, Ishii T, Shinmyozu K, Nakayama J, Sugasawa K, Nishitani H.

Mol Cell Biol. 2012 Jun;32(12):2279-88. doi: 10.1128/MCB.06506-11. Epub 2012 Apr 9.

29.

Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs.

Stathopoulou A, Roukos V, Petropoulou C, Kotsantis P, Karantzelis N, Nishitani H, Lygerou Z, Taraviras S.

PLoS One. 2012;7(3):e34621. doi: 10.1371/journal.pone.0034621. Epub 2012 Mar 30.

30.

[Chemotherapy for gastrointestinal cancer in elderly patients].

Nishitani H, Takiuchi H, Asaishi K, Kuwakado S, Kii T, Yoshida M, Goto M.

Gan To Kagaku Ryoho. 2011 Oct;38(10):1591-4. Japanese.

PMID:
21996953
31.

Using the MDCT thick slab MinIP method for the follow-up of pulmonary emphysema.

Lan H, Nishitani H, Nishihara S, Ueno J, Takao S, Iwamoto S, Kawanaka T, Mahmut M, Qingge S.

J Med Invest. 2011 Aug;58(3-4):175-9.

32.

Measurements of multidetector CT surface dose distributions using a film dosimeter and chest phantom.

Tominaga M, Kawataa Y, Niki N, Moriyama N, Yamada K, Ueno J, Nishitani H.

Med Phys. 2011 May;38(5):2467-78.

PMID:
21776782
33.

Hypothyroidism caused by phenobarbital affects patterns of estrous cyclicity in rats.

Li Y, Kumazawa T, Ishiguro T, Kawakami Y, Nishitani H, Tagawa Y, Matsumoto Y.

Congenit Anom (Kyoto). 2011 Jun;51(2):55-61. doi: 10.1111/j.1741-4520.2011.00314.x.

PMID:
21595753
34.

Dynamic recruitment of licensing factor Cdt1 to sites of DNA damage.

Roukos V, Kinkhabwala A, Colombelli J, Kotsantis P, Taraviras S, Nishitani H, Stelzer E, Bastiaens P, Lygerou Z.

J Cell Sci. 2011 Feb 1;124(Pt 3):422-34. doi: 10.1242/jcs.074229. Epub 2011 Jan 11.

35.

Clinical Application of MR Spectroscopy and Imaging of Brain Tumor.

Morita N, Harada M, Otsuka H, Melhem ER, Nishitani H.

Magn Reson Med Sci. 2010;9(4):167-75. Review.

36.

Positively charged residues located downstream of PIP box, together with TD amino acids within PIP box, are important for CRL4(Cdt2) -mediated proteolysis.

Michishita M, Morimoto A, Ishii T, Komori H, Shiomi Y, Higuchi Y, Nishitani H.

Genes Cells. 2011 Jan;16(1):12-22. doi: 10.1111/j.1365-2443.2010.01464.x. Epub 2010 Dec 9.

37.

Temporomandibular joint and 3.0 T pseudodynamic magnetic resonance imaging. Part 2: evaluation of articular disc obscurity.

Iwasaki H, Kubo H, Harada M, Nishitani H, Ohashi Y.

Dentomaxillofac Radiol. 2010 Dec;39(8):486-93. doi: 10.1259/dmfr/92017549.

38.

Temporomandibular joint and 3.0 T pseudodynamic magnetic resonance imaging. Part 1: evaluation of condylar and disc dysfunction.

Iwasaki H, Kubo H, Harada M, Nishitani H.

Dentomaxillofac Radiol. 2010 Dec;39(8):475-85. doi: 10.1259/dmfr/29741224.

39.

Proliferating cell nuclear antigen-dependent rapid recruitment of Cdt1 and CRL4Cdt2 at DNA-damaged sites after UV irradiation in HeLa cells.

Ishii T, Shiomi Y, Takami T, Murakami Y, Ohnishi N, Nishitani H.

J Biol Chem. 2010 Dec 31;285(53):41993-2000. doi: 10.1074/jbc.M110.161661. Epub 2010 Oct 7.

40.

Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors.

Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, Nishitani H.

J Med Invest. 2010 Aug;57(3-4):270-4.

41.

Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.

Takahari D, Shimada Y, Takeshita S, Nishitani H, Takashima A, Okita N, Hirashima Y, Kato K, Hamaguchi T, Yamada Y, Shirao K.

Gastric Cancer. 2010 Aug;13(3):186-90. doi: 10.1007/s10120-010-0557-0. Epub 2010 Sep 5.

PMID:
20820988
42.

Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument.

Harada M, Taki MM, Nose A, Kubo H, Mori K, Nishitani H, Matsuda T.

J Autism Dev Disord. 2011 Apr;41(4):447-54. doi: 10.1007/s10803-010-1065-0.

PMID:
20652388
43.
44.

[Comparison of dose distribution on radiographic film and radiochromic film for intensity modulated radiation therapy].

Sasaki M, Tominaga M, Ikushima H, Kishi T, Kawashita T, Hara Y, Fukunaga Y, Yamada K, Oita M, Nishitani H.

Nihon Hoshasen Gijutsu Gakkai Zasshi. 2010 May 20;66(5):525-34. Japanese.

45.

Manifestations of the female reproductive organs on MR images: changes induced by various physiologic states.

Takeuchi M, Matsuzaki K, Nishitani H.

Radiographics. 2010 Jul-Aug;30(4):1147. doi: 10.1148/rg.e39. Epub 2010 May 4.

PMID:
20442336
46.

Incidence and clinical correlation of intracranial hemorrhages observed by 3-tesla gradient echo T(2)*-weighted images following intravenous thrombolysis with recombinant tissue plasminogen activator.

Harada M, Morita N, Uno M, Satomi J, Izumi Y, Asanuma K, Nishitani H, Kaji R, Nagahiro S.

Cerebrovasc Dis. 2010;29(6):571-5. doi: 10.1159/000306644. Epub 2010 Apr 8.

PMID:
20375500
47.

Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses.

Takeuchi M, Matsuzaki K, Nishitani H.

J Comput Assist Tomogr. 2010 Mar-Apr;34(2):173-6. doi: 10.1097/RCT.0b013e3181c2f0a2.

PMID:
20351498
48.

Radiographic comparison between male and female patients with lumbar spondylolysis.

Takao S, Sakai T, Sairyo K, Kondo T, Ueno J, Yasui N, Nishitani H.

J Med Invest. 2010 Feb;57(1-2):133-7.

49.

Use of a diagnostic positron emission tomography-computed tomography system for planning radiotherapy positioning: distortion of the tabletop.

Kishida Y, Ikushima H, Sasaki M, Hara Y, Oita M, Nishitani H.

Jpn J Radiol. 2010 Feb;28(2):143-8. doi: 10.1007/s11604-009-0398-0. Epub 2010 Feb 26.

PMID:
20182849
50.

High-dose-rate brachytherapy for patients with maxillary gingival carcinoma using a novel customized intraoral mold technique.

Kudoh T, Ikushima H, Kudoh K, Tokuyama R, Osaki K, Furutani S, Kawanaka T, Kubo A, Nishitani H, Honda E.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Feb;109(2):e102-8. doi: 10.1016/j.tripleo.2009.10.019.

PMID:
20123391

Supplemental Content

Loading ...
Support Center